Investigation of gene and cellular therapies to cure maple syrup urine disease (MSUD) in a genetically engineered mouse model

2008 2008

Other formats: Order a copy

Abstract (summary)

MSUD is a serious liver-based metabolic disorder caused by a deficiency in the branched-chain alpha-ketoacid dehydrogenase (BCKDH) complex. Resulting branched-chain amino acid (BCAA) accretion in the body mainly affects the brain, which in most cases results in permanent neurological dysfunction or death without life-long attentive care. Recently it was shown liver transplantation alone restored BCKDH to a level sufficient to correct MSUD. To test novel therapies, a mouse model of intermediate MSUD (iMSUD) was created (Homanics et al., 2006), which mimicked human iMSUD. Therefore, this dissertation focused on the investigation of liver-directed therapeutic approaches to correct MSUD.

In the first aim, iMSUD mice were further characterized and determined to closely mirror the human disease phenotype. iMSUD mice suffered from developmental delay, seizures, and altered brain amino acid and neurotransmitter concentration. iMSUD brains also displayed histological abnormalities while liver morphology was normal.

In the second aim, adeno-associated viral (AAV) vectors were used to deliver E2 to the liver. However, no significant improvement was determined in AAV-treated iMSUD mice compared to controls. The most likely reasons this study was unsuccessful were low treatment dose, a weak albumin promoter, and possible competition and interaction between AAV-derived and iMSUD transgene-derived E2.

The third aim focused on hepatocyte transplantation (HTx). iMSUD-HTx mice had a 75% reduction in BCAA/alanine levels compared to iMSUD controls. BCKDH activity was increased, and Real Time qPCR detected donor-derived E2 in the liver. Dopamine and serotonin, along with several related metabolites, were corrected to control levels. Body weight at weaning and survival were also significantly improved in iMSUD-HTx mice.

The fourth aim focused on differentiated embryonic stem cell (ESC) transplantation. Differentiated ESCs expressed liver-specific markers after 3 days in culture and BCKDH activity was significantly increased over undifferentiated ESC populations. Liver-like ESC engraftment was verified up to 1 month following transplantation into wildtype mouse liver.

In summary, iMSUD mice were determined to be a superior model to test novel liver-directed therapies. Our findings of partial metabolic correction of iMSUD in a mouse model by HTx were very encouraging. Therefore, liver-directed therapeutic intervention for human MSUD should be investigated further.

Indexing (details)

0369: Genetics
0564: Medicine
Identifier / keyword
Health and environmental sciences; Biological sciences; Adeno-associated virus; Embryonic stem cells; Gene therapy; Hepatocyte transplant; Maple syrup urine disease
Investigation of gene and cellular therapies to cure maple syrup urine disease (MSUD) in a genetically engineered mouse model
Skvorak, Kristen J.
Number of pages
Publication year
Degree date
School code
DAI-B 69/12, Dissertation Abstracts International
Place of publication
Ann Arbor
Country of publication
United States
University of Pittsburgh
University location
United States -- Pennsylvania
Source type
Dissertations & Theses
Document type
Dissertation/thesis number
ProQuest document ID
Database copyright ProQuest LLC; ProQuest does not claim copyright in the individual underlying works.
Document URL
Access the complete full text

You can get the full text of this document if it is part of your institution's ProQuest subscription.

Try one of the following:

  • Connect to ProQuest through your library network and search for the document from there.
  • Request the document from your library.
  • Go to the ProQuest login page and enter a ProQuest or My Research username / password.